Phase 3 randomized study of loncastuximab tesirine in combination with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL (LOTIS-5).-MedSci.cn

Phase 3 randomized study of loncastuximab tesirine in combination with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL (LOTIS-5).

Hamadani, M; Linhares, Y; Gandhi, M; Chung, M; Adamis, H; Ungar, D; Carlo-Stella, C; Kingsley, E; Depaus, J; Snauwaert, S; Kwiatek, M; Lopez-Jimenez, J

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16):

科室
- - 订阅+
  - 更多科室
工具
服务